Neil Dogra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Neil Dogra has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aarthi Arun
University of Rochester School of Medicine and Dentistry, Rochester, NY
1 shared publication - Aditya S. Gunturi
School of Medicine and Dentistry, University of Rochester, Rochester, United States of America
1 shared publication - Alan M. Delmerico
Institute for Community Health Promotion, Buffalo State University, Buffalo, NY, USA
1 shared publication - Carl Ceraolo
Department of Urology, University of Rochester Medical Center, Rochester, New York
1 shared publication - Galen Cheng
Department of Urology, University of Rochester Medical Center, Rochester, NY
1 shared publication - Hossein Mousazadeh
Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Environmental Medicine and Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA
1 shared publication
Latest Publications
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
Obstructive Sleep Apnea as a Modifier of Systemic Thromboembolic Risk Following Retinal Vein Occlusion
Background: Systemic vascular risk stratification following retinal vein occlusion (RVO) remains limited. We evaluated whether comorbid obstructive sleep apnea (OSA) modifies thromboembolic risk following RVO. Methods: Retrospective cohort study using TriNetX Analytics Network. RVO patients with versus without prior OSA were matched 1:1 on demographics and comorbidities. Incident outcomes at 1, 3, and 5 years included hazard ratios (HR [95% confidence interval]) of anticoagulation initiation, composite venous thromboembolism (VTE; pulmonary embolism or deep vein thrombosis), myocardial infarction, composite arterial thromboembolism (ATE; cerebral infarction, transient ischemic attack, or arterial embolism), cerebral infarction, hemorrhagic stroke, carotid disease, and mortality. Secondary matched analysis compared central RVO (CRVO) versus branch RVO (BRVO) among OSA patients. Results: After matching, 10,728 patients remained per cohort. OSA was associated with increased anticoagulation initiation (1 year: HR 1.38 [1.18-1.61]; 3 years: HR 1.29 [1.16-1.44]; 5 years: HR 1.32 [1.19-1.45]), VTE (1 year: HR 1.48 [1.20-1.82]; 3 years: HR 1.46 [1.26-1.69]; 5 years: HR 1.44 [1.26-1.63]), and myocardial infarction (3 years: HR 1.21 [1.06-1.38]; 5 years: HR 1.17 [1.04-1.31]). ATE, cerebral infarction, hemorrhagic stroke, and carotid disease hazards were similar. All-cause mortality was lower among OSA patients at 3 years (HR 0.88 [0.80-0.96]) and 5 years (HR 0.90 [0.83-0.98]). Among OSA patients, CRVO showed higher mortality than BRVO (1 year: HR 1.50 [1.20-1.89]; 3 years: HR 1.29 [1.11-1.49]; 5 years: HR 1.33 [1.18-1.51]). Conclusions: Comorbid OSA identifies a subgroup of RVO patients at higher hazard for venous thromboembolism and myocardial infarction. Within this subgroup, CRVO may carry higher all-cause mortality hazard than BRVO.
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
Obstructive Sleep Apnea as a Modifier of Systemic Thromboembolic Risk Following Retinal Vein Occlusion
Background: Systemic vascular risk stratification following retinal vein occlusion (RVO) remains limited. We evaluated whether comorbid obstructive sleep apnea (OSA) modifies thromboembolic risk following RVO. Methods: Retrospective cohort study using TriNetX Analytics Network. RVO patients with versus without prior OSA were matched 1:1 on demographics and comorbidities. Incident outcomes at 1, 3, and 5 years included hazard ratios (HR [95% confidence interval]) of anticoagulation initiation, composite venous thromboembolism (VTE; pulmonary embolism or deep vein thrombosis), myocardial infarction, composite arterial thromboembolism (ATE; cerebral infarction, transient ischemic attack, or arterial embolism), cerebral infarction, hemorrhagic stroke, carotid disease, and mortality. Secondary matched analysis compared central RVO (CRVO) versus branch RVO (BRVO) among OSA patients. Results: After matching, 10,728 patients remained per cohort. OSA was associated with increased anticoagulation initiation (1 year: HR 1.38 [1.18-1.61]; 3 years: HR 1.29 [1.16-1.44]; 5 years: HR 1.32 [1.19-1.45]), VTE (1 year: HR 1.48 [1.20-1.82]; 3 years: HR 1.46 [1.26-1.69]; 5 years: HR 1.44 [1.26-1.63]), and myocardial infarction (3 years: HR 1.21 [1.06-1.38]; 5 years: HR 1.17 [1.04-1.31]). ATE, cerebral infarction, hemorrhagic stroke, and carotid disease hazards were similar. All-cause mortality was lower among OSA patients at 3 years (HR 0.88 [0.80-0.96]) and 5 years (HR 0.90 [0.83-0.98]). Among OSA patients, CRVO showed higher mortality than BRVO (1 year: HR 1.50 [1.20-1.89]; 3 years: HR 1.29 [1.11-1.49]; 5 years: HR 1.33 [1.18-1.51]). Conclusions: Comorbid OSA identifies a subgroup of RVO patients at higher hazard for venous thromboembolism and myocardial infarction. Within this subgroup, CRVO may carry higher all-cause mortality hazard than BRVO.